Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • 1002 Single cell transcriptomi...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
Export Ready — 
1002 Single cell transcriptomics in kidney tissue from African American patients enrolled in the accelerating medicines partnership (AMP) implicates tubular cells in the pathogenesis of APOL1 associated lupus nephritis

1002 Single cell transcriptomics in kidney tissue from African American patients enrolled in the accelerating medicines partnership (AMP) implicates tubular cells in the pathogenesis of APOL1 associated lupus nephritis

Bibliographic Details
Main Authors: Richard Furie, Brad Rovin, Michelle Petri, Judith A James, Kenneth Kalunian, Maria Dall’Era, Jill Buyon, Chaim Putterman, Peter Izmirly, Betty Diamond, David Wofsy, Ming Wu, Soumya Raychaudhuri, Philip M Carlucci, Qian Xiao, Nir Hacohen, Jennifer Anolik, H Michael Belmont, Robert Clancy, Kelly Ruggles, ANNE DAVIDSON, Deepak Rao, Celine C Berthier, Andrea Fava, Diane Kamen, Joel Guthridge, Arnon Arazi, Jose Monroy-Trujillo, Kristin Haag, William Apruzzese, Fernanda Payan-Schober, Kerry Cho, Joseph Mears, Wade DeJager, Paul Hoover, Kristina Deonaraine, Siddarth Gurajala, Derek Fine, Devyn Zaminski, Jasmine Shwetar, Katie Preisinger, Sethu Madhavan
Format: Article
Language:English
Published: BMJ Publishing Group 2024-05-01
Series:Lupus Science and Medicine
  • Holdings
  • Description
  • Similar Items
  • Staff View

Similar Items

  • Longitudinal patterns and predictors of response to standard-of-care therapy in lupus nephritis: data from the Accelerating Medicines Partnership Lupus Network
    by: Peter M. Izmirly, et al.
    Published: (2024-02-01)
  • Clinical implications of discordance between anti-dsDNA antibodies by multiplex flow immunoassay and Crithidia luciliae assay in a multiethnic racial cohort of patients with SLE
    by: Amit Saxena, et al.
    Published: (2023-08-01)
  • LO-006 Change in urinary biomarkers at three months predicts 1-year treatment response of lupus nephritis better than proteinuria
    by: Richard Furie, et al.
    Published: (2023-07-01)
  • 1702 Patients enrolled in the accelerating medicines partnership (AMP) RA/SLE network with isolated renal disease report minimal quality of life impairment on PROMIS-29 compared to patients with extrarenal symptoms
    by: Richard Furie, et al.
    Published: (2022-12-01)
  • 310 ELUCIDATE-Epigenetics; lupus urine cells in decoding APOL1 transmutation effect
    by: Jill Buyon, et al.
    Published: (2024-05-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs